Generics versus Big Pharma

Yet over the past decade in particular, most of the Big Pharma’s have adopted small molecule generics in one shape or form into their overall business model. And many of them openly talk about the “innovation headroom” that a healthy low-priced generics market enables i.e. the money saved on off-patent drugs can be used to fund high-priced new innovations. They have recognized that they cannot fight the realities of aging populations and healthcare economics.


    Related Conference of Generics versus Big Pharma

    December 05-06, 2023

    2nd World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    February 01-02, 2024

    37th World Congress on Pharmacology

    Dubai, UAE
    February 22-23, 2024

    34th Annual European Pharma Congress

    Zurich, Switzerland
    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Generics versus Big Pharma Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in